|
1
|
Yui Y, Itoh K, Yoshioka K, et al:
Mesenchymal mode of migration participates in pulmonary metastasis
of mouse osteosarcoma LM8. Clin Exp Metastasis. 27:619–630. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bianchi E, Artico M, Di Cristofano C, et
al: Growth factors, their receptor expression and markers for
proliferation of endothelial and neoplastic cells in human
osteosarcoma. Int J Immunopathol Pharmacol. 26:621–632.
2013.PubMed/NCBI
|
|
3
|
Rainusso N, Wang LL and Yustein JT: The
adolescent and young adult with cancer: state of the art - bone
tumors. Curr Oncol Rep. 15:296–307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fayda M, Kebudi R, Dizdar Y, Gorgun O, Gun
F, Aksu G and Ayan I: Spontaneous pneumothorax in children with
osteosarcoma: report of three cases and review of the literature.
Acta Chir Belg. 112:378–381. 2012.PubMed/NCBI
|
|
5
|
Ritter J and Bielack SS: Osteosarcoma. Ann
Oncol. 21:vii320–vii325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bacci G, Longhi A, Versari M, Mercuri M,
Briccoli A and Picci P: Prognostic factors for osteosarcoma of the
extremity treated with neoadjuvant chemotherapy: 15-year experience
in 789 patients treated at a single institution. Cancer.
106:1154–1161. 2006.PubMed/NCBI
|
|
7
|
Li Z, Liao Q, Wu Y, et al: Upregulation of
a disintegrin and metalloprotease 8 influences tumor metastasis and
prognosis in patients with osteosarcoma. Pathol Oncol Res.
18:657–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sarkar S, Dubaybo H, Ali S, et al:
Down-regulation of miR-221 inhibits proliferation of pancreatic
cancer cells through up-regulation of PTEN, p27kip1,
p57kip2, and PUMA. Am J Cancer Res. 3:465–477.
2013.PubMed/NCBI
|
|
9
|
Sekine S, Shimada Y, Nagata T, et al: Role
of aquaporin-5 in gallbladder carcinoma. Eur Surg Res. 51:108–117.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Guessous F, DiPierro C, et al:
Interactions between PTEN and the c-Met pathway in glioblastoma and
implications for therapy. Mol Cancer Ther. 8:376–385. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schneider E, Keppler R, Prawitt D, et al:
Migration of renal tumor cells depends on dephosphorylation of Shc
by PTEN. Int J Oncol. 38:823–831. 2011.PubMed/NCBI
|
|
12
|
Shukla S, Pia Patric IR, Thinagararjan S,
et al: A DNA methylation prognostic signature of glioblastoma:
identification of NPTX2-PTEN-NF-κB nexus. Cancer Res. 73:6563–6573.
2013.PubMed/NCBI
|
|
13
|
Rogers HA, Mayne C, Chapman RJ, Kilday JP,
Coyle B and Grundy RG: PI3K pathway activation provides a novel
therapeutic target for pediatric ependymoma and is an independent
marker of progression-free survival. Clin Cancer Res. 19:6450–6460.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Colangelo T, Fucci A, Votino C, et al:
MicroRNA-130b promotes tumor development and is associated with
poor prognosis in colorectal cancer. Neoplasia. 15:1218–1231.
2013.
|
|
15
|
Aoyama D, Hashimoto N, Sakamoto K, et al:
Involvement of TGFβ-induced phosphorylation of the PTEN C-terminus
on TGFβ-induced acquisition of malignant phenotypes in lung cancer
cells. PLoS One. 8:e811332013.
|
|
16
|
Carver BS, Tran J, Gopalan A, et al:
Aberrant ERG expression cooperates with loss of PTEN to promote
cancer progression in the prostate. Nat Genet. 41:619–624. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dey N, Crosswell HE, De P, Parsons R, Peng
Q, Su JD and Durden DL: The protein phosphatase activity of PTEN
regulates SRC family kinases and controls glioma migration. Cancer
Res. 68:1862–1871. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sze KM, Wong KL, Chu GK, Lee JM, Yau TO
and Ng IO: Loss of phosphatase and tensin homolog enhances cell
invasion and migration through AKT/Sp-1 transcription factor/matrix
metalloproteinase 2 activation in hepatocellular carcinoma and has
clinicopathologic significance. Hepatology. 53:1558–1569. 2011.
View Article : Google Scholar
|
|
19
|
Marsh Durban V, Jansen M, Davies EJ,
Morsink FH, Offerhaus GJ and Clarke AR: Epithelial-specific loss of
PTEN results in colorectal juvenile polyp formation and
invasive cancer. Am J Pathol. 184:86–91. 2014.PubMed/NCBI
|
|
20
|
Metcalfe C, Alicke B, Crow A, et al: PTEN
loss mitigates the response of medulloblastoma to Hedgehog pathway
inhibition. Cancer Res. 73:7034–7042. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garcia-Carracedo D, Turk AT, Fine SA, et
al: Loss of PTEN expression is associated with poor prognosis in
patients with intraductal papillary mucinous neoplasms of the
pancreas. Clin Cancer Res. 19:6830–6841. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leinonen KA, Saramäki OR, Furusato B, et
al: Loss of PTEN is associated with aggressive behavior in
ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev.
22:2333–2344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matsuda S, Nakanishi A, Wada Y and
Kitagishi Y: Roles of PI3K/ AKT/PTEN pathway as a target for
pharmaceutical therapy. Open Med Chem J. 7:23–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Germani A, Matrone A, Grossi V, et al:
Targeted therapy against chemoresistant colorectal cancers:
inhibition of p38α modulates the effect of cisplatin in vitro and
in vivo through the tumor suppressor FoxO3A. Cancer
Lett. 344:110–118. 2013.PubMed/NCBI
|
|
25
|
Tamura M, Gu J, Takino T and Yamada KM:
Tumor suppressor PTEN inhibition of cell invasion, migration, and
growth: differential involvement of focal adhesion kinase and
p130Cas. Cancer Res. 59:442–449. 1999.PubMed/NCBI
|
|
26
|
Alimonti A, Carracedo A, Clohessy JG, et
al: Subtle variations in Pten dose determine cancer
susceptibility. Nat Genet. 42:454–458. 2010.
|
|
27
|
Gu J, Tamura M, Pankov R, Danen EH, Takino
T, Matsumoto K and Yamada KM: Shc and FAK differentially regulate
cell motility and directionality modulated by PTEN. J Cell Biol.
146:389–403. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Crompton BD, Carlton AL, Thorner AR, et
al: High-throughput tyrosine kinase activity profiling identifies
FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res.
73:2873–2883. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Caino MC, Chae YC, Vaira V, et al:
Metabolic stress regulates cytoskeletal dynamics and metastasis of
cancer cells. J Clin Invest. 123:2907–2920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Castillo-Sanchez R, Villegas-Comonfort S,
Galindo-Hernandez O, Gomez R and Salazar EP:
Benzo-[a]-pyrene induces FAK activation and cell migration
in MDA-MB-231 breast cancer cells. Cell Biol Toxicol. 29:303–319.
2013.
|
|
31
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hanna SC, Krishnan B, Bailey ST, et al:
HIF1α and HIF2α independently activate SRC to promote melanoma
metastases. J Clin Invest. 123:2078–2093. 2013.
|
|
33
|
Miwa S, Sugimoto N, Yamamoto N, et al:
Caffeine induces apoptosis of osteosarcoma cells by inhibiting
AKT/mTOR/S6K, NF-κB and MAPK pathways. Anticancer Res.
32:3643–3649. 2012.PubMed/NCBI
|
|
34
|
Namløs HM, Meza-Zepeda LA, Barøy T, et al:
Modulation of the osteosarcoma expression phenotype by microRNAs.
PLoS One. 7:e480862012.PubMed/NCBI
|
|
35
|
Luo X, Sharff KA, Chen J, He TC and Luu
HH: S100A6 expression and function in human osteosarcoma. Clin
Orthop Relat Res. 466:2060–2070. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cai C, Rodepeter FR, Rossmann A, et al:
Nef from SIVmac239 decreases proliferation and migration
of adenoid-cystic carcinoma cells and inhibits angiogenesis. Oral
Oncol. 47:847–854. 2011.
|
|
37
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment - where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Muhlbradt E, Ma J, Severi G, et al:
Variant NKX3.1 and serum IGF-1: investigation of interaction in
prostate cancer. Genes Cancer. 4:535–545. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Davies EJ, Marsh Durban V, Meniel V,
Williams GT and Clarke AR: PTEN loss and KRAS
activation leads to the formation of serrated adenomas and
metastatic carcinoma in the mouse intestine. J Pathol. 233:27–38.
2014. View Article : Google Scholar
|
|
40
|
Paul P, Qiao J, Kim KW, et al: Targeting
gastrin-releasing peptide suppresses neuroblastoma progression via
upregulation of PTEN signaling. PLoS One. 8:e725702013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012.PubMed/NCBI
|
|
42
|
Krausch M, Raffel A, Anlauf M, et al: Loss
of PTEN expression in neuroendocrine pancreatic tumors. Horm Metab
Res. 43:865–871. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dasari VR, Kaur K, Velpula KK, et al:
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem
cells inhibits migration via downregulation of the PI3K/Akt
pathway. PLoS One. 5:e103502010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mierke CT: The role of focal adhesion
kinase in the regulation of cellular mechanical properties. Phys
Biol. 10:0650052013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ji HF, Pang D, Fu SB, Jin Y, Yao L, Qi JP
and Bai J: Overexpression of focal adhesion kinase correlates with
increased lymph node metastasis and poor prognosis in
non-small-cell lung cancer. J Cancer Res Clin Oncol. 139:429–435.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ko BS, Jan YJ, Chang TC, et al:
Upregulation of focal adhesion kinase by 14-3-3ɛ via NFκB
activation in hepatocellular carcinoma. Anticancer Agents Med Chem.
13:555–562. 2013.PubMed/NCBI
|
|
47
|
Provenzano PP, Inman DR, Eliceiri KW,
Beggs HE and Keely PJ: Mammary epithelial-specific disruption of
focal adhesion kinase retards tumor formation and metastasis in a
transgenic mouse model of human breast cancer. Am J Pathol.
173:1551–1565. 2008. View Article : Google Scholar
|
|
48
|
Baranwal S, Wang Y, Rathinam R, et al:
Molecular characterization of the tumor-suppressive function of
nischarin in breast cancer. J Natl Cancer Inst. 103:1513–1528.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Golubovskaya VM and Cance W: Focal
adhesion kinase and p53 signal transduction pathways in cancer.
Front Biosci. 15:901–912. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shih YW, Chien ST, Chen PS, Lee JH, Wu SH
and Yin LT: α-mangostin suppresses phorbol 12-myristate
13-acetate-induced MMP-2/MMP-9 expressions via αvβ3
integrin/FAK/ERK and NF-κB signaling pathway in human lung
adenocarcinoma A549 cells. Cell Biochem Biophys. 58:31–44.
2010.
|
|
51
|
Pal S, Ganguly KK and Chatterjee A:
Extracellular matrix protein fibronectin induces matrix
metalloproteinases in human prostate adenocarcinoma cells PC-3.
Cell Commun Adhes. 20:105–114. 2013. View Article : Google Scholar
|
|
52
|
Poudel B and Kim DK, Ki HH, Kwon YB, Lee
YM and Kim DK: Downregulation of ERK signaling impairs U2OS
osteosarcoma cell migration in collagen matrix by suppressing MMP9
production. Oncol Lett. 7:215–218. 2014.PubMed/NCBI
|
|
53
|
Lu XS, Sun W, Ge CY, Zhang WZ and Fan YZ:
Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin
signaling pathways to tumor growth and vasculogenic mimicry of
gallbladder carcinomas. Int J Oncol. 42:2103–2115. 2013.
|
|
54
|
Matsumoto Y, Tanaka K, Harimaya K,
Nakatani F, Matsuda S and Iwamoto Y: Small GTP-binding protein,
Rho, both increased and decreased cellular motility, activation of
matrix metalloproteinase 2 and invasion of human osteosarcoma
cells. Jpn J Cancer Res. 92:429–438. 2001. View Article : Google Scholar
|
